Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak More >
Brian Bloom is a cofounder of Bloom Burton & Co. and serves as the firm's president and head of institutional sales and capital market activities. By forging unique relationships with international healthcare-specialized investors, Bloom attracts capital for growing companies seeking to accelerate returns for investors. Before co-founding Bloom Burton, Bloom spent six years at Dundee Securities in the healthcare and biotechnology institutional sales and equity research groups. Earlier in his career, he spent two years in the equity research group at a New York-based merchant banking firm, SCO Group, and was an investment banking analyst at M&A advisory firm, Molecular Securities. Bloom is a member of the Life Sciences Advisory Board at the National Research Council of Canada and the Board of Directors at BIOTECanada. Bloom received an bachelor's degree with honors in biochemistry from McMaster University and subsequently studied at the Mount Sinai Graduate School for Biological Sciences of New York University with a focus in molecular endocrinology and biophysics.
Stunning Potential for Upside in Canadian Biotech: Brian Bloom (6/12/14) You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling skill sets and pipelines. In this interview with The Life Sciences Report, Bloom talks about his firm's upcoming conference and presents a detailed picture of four very interesting companies that could return doubles, triples or more.
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke More >
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke More >
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke More >